BioDir 产业动态
455 条内容- ▶ Regenxbio基因疗法数据积极但股价大跌 2026-05-18
- ▶ 世卫组织宣布埃博拉疫情为国际突发公共卫生事件 2026-05-17
- ▶ FDA局长马卡里辞职 2026-05-16
- ▶ FDA药物中心主任霍格预计离职 2026-05-15
- ▶ RAGE受体关联衰老与乳腺癌转移 2026-05-15
- ▶ ALS多组学研究揭示免疫浸润机制 2026-05-15
- ▶ 生物制药并购强劲，大型交易减少 2026-05-15
- ▶ 安进加强340B计划监管 2026-05-15
- ▶ 基因治疗融资回暖 2026-05-15
- ▶ 5月15日生物医药简报 2026-05-15
- ▶ 生物医药行业人事变动汇总 2026-05-15
- ▶ 研究关注：Biopharma deal and M&A values soar in early 2026 2026-05-15
- ▶ 研究关注：Validity of Actelion patent hinges on temperature 2026-05-15
- ▶ 研究关注：EU reaches Critical Medicines Act pact to tackle drug shortages 2026-05-15
- ▶ 研究关注：Sonomind raises €20M for ultrasound neuromodulation technology 2026-05-15
- ▶ 研究关注：Authorities work to quickly sequence Ebola strain in latest outbreak 2026-05-15
- ▶ 5月15日临床试验快报 2026-05-15
- ▶ 2026年5月15日生物医药融资汇总 2026-05-15
- ▶ 2026年5月15日监管动态 2026-05-15
- ▶ 研究关注：FDA hold puts Aardvark Prader-Willi drug in limbo 2026-05-15
- ▶ 研究关注：Supreme Court preserves access to abortion pill by mail 2026-05-15
- ▶ 研究关注：Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers 2026-05-15
- ▶ 研究关注：Candel reports prostate cancer drug's long-term data ahead of FDA filing 2026-05-15
- ▶ 研究关注：Post-Hoc Live: Makary's out at FDA and what comes next 2026-05-15
- ▶ 研究关注：Authorities work to quickly sequence Ebola strain in latest outbreak 2026-05-15
- ▶ 研究关注：Aardvark's next move after clinical hold; Alumis' verdict on Acelyrin asset 2026-05-15
- ▶ 研究关注：ASGCT 2026: Beverly Davidson Offers Vehicle and Route for Huntington’s Disease Gene Therapy 2026-05-15
- ▶ 研究关注：ASGCT 2026: AI-Optimized Cas12l Gene Editor Offers Compact Cas9 Alternative 2026-05-15
- ▶ 研究关注：India’s pharma industry is going global. But can it catch up to China? 2026-05-15
- ▶ 研究关注：HCW Biologics’ HCW11-040 prevents bronchopulmonary dysplasia 2026-05-15
- ▶ 研究关注：Ensem’s ETX-929 is candidate for KRAS mutant tumors 2026-05-15
- ▶ 研究关注：KSI-028 suppresses STING-driven inflammation 2026-05-15
- ▶ 研究关注：New KRAS mutant inhibitors reported in Université de Montréal patent 2026-05-15
- ▶ 研究关注：NTX-819, a novel mGlu7 NAM for psychiatric disorders 2026-05-15
- ▶ 研究关注：Antelope Therapeutics patents new antibody-drug conjugates for cancer 2026-05-15
- ▶ 研究关注：Maipl Therapeutics advances MA-4604 for endometriosis 2026-05-15
- ▶ 研究关注：Hangzhou Institute of Medicine discovers new CDK2/cyclin E1 inhibitors 2026-05-15
- ▶ 研究关注：Camp4 studies CMP-002 in SYNGAP1 haploinsufficient mouse model 2026-05-15
- ▶ 研究关注：Financing at Create Medicines to advance in vivo CAR therapies 2026-05-15
- ▶ 研究关注：Sanofi identifies YAP1/TEAD and TAZ/TEAD interaction inhibitors 2026-05-15
- ▶ 研究关注：ZMS-4084 shows robust antitumor efficacy in MSI-H cancer models 2026-05-15
- ▶ 研究关注：ASGCT 2026: Directed evolution in gene therapy 2026-05-15
- ▶ 研究关注：CSPC Megalith Biopharmaceutical discloses new CDCP1-targeting ADCs 2026-05-15
- ▶ 研究关注：Launch of CGTxchange to reactivate cell and gene therapy programs 2026-05-15
- ▶ 研究关注：ASGCT 2026: Rare Instance of AAV Integration into Human Genome Linked to Brain Tumor 2026-05-15
- ▶ 研究关注：M&A isn’t just for big pharma. Mid-size companies are stepping up deal hunts 2026-05-15
- ▶ 研究关注：Andrea Pfeifer ends 23-year reign at AC Immune; Acadia's top R&D exec announces retirement 2026-05-15
- ▶ 研究关注：#ASGCT26: A Zillow-like marketplace for abandoned gene therapies goes live 2026-05-15
- ▶ 研究关注：DNA‑Guided CRISPR Suggests a New Direction for RNA Editing 2026-05-15
- ▶ 研究关注：Supreme Court preserves mail access for abortion pill 2026-05-15
- ▶ 研究关注：Implantable Living Materials Contain Infection-Sensing Bacteria That Release Therapeutics 2026-05-14
- ▶ 研究关注：Molecular Anchors Help Tumor Therapies Stay Longer on Cancer Cells 2026-05-14
- ▶ 研究关注：Create Medicines raises $122M to bolster in vivo CAR-T therapies 2026-05-14
- ▶ 研究关注：USPTO doubles down on inconsistencies in dual IPR-court action 2026-05-14
- ▶ 研究关注：Biogen AD drug shows tau, cognition benefit, despite trial miss 2026-05-14
- ▶ 研究关注：Andes virus cases rise to 11; Hondius passengers in quarantine to June 21 2026-05-14
- ▶ 研究关注：Will FDA show Affinity for fast yes to Regenxbio in DMD? 2026-05-14
- ▶ 研究关注：Medical devices evolving into intelligent, adaptive systems 2026-05-14
- ▶ 研究关注：Regulatory actions for May 14, 2026 2026-05-14
- ▶ 研究关注：In the clinic for May 14, 2026 2026-05-14
- ▶ 研究关注：Financings for May 14, 2026 2026-05-14
- ▶ 研究关注：Other news to note for May 14, 2026 2026-05-14
- ▶ 研究关注：Appointments and advancements for May 14, 2026 2026-05-14
- ▶ 研究关注：Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal 2026-05-14
- ▶ 研究关注：Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal 2026-05-14
- ▶ 研究关注：Biogen pushing tau drug forward despite Alzheimer’s study failure 2026-05-14
- ▶ 研究关注：With new data, Regenxbio to seek FDA approval of Duchenne gene therapy 2026-05-14
- ▶ 研究关注：ASGCT 2026: Uncovering the mechanisms of AAV toxicity 2026-05-14
- ▶ 研究关注：Vivozon reports new dual 5-HT2A/dopamine D2 receptor antagonists 2026-05-14
- ▶ 研究关注：Pfizer discloses new dual calcitonin/amylin receptor agonists 2026-05-14
- ▶ 研究关注：KHN-921 gains IND clearance for MYBPC3 -associated HCM 2026-05-14
- ▶ 研究关注：Epirium’s 15-PGDH inhibitor IBD candidates improve disease outcomes in models 2026-05-14
- ▶ 研究关注：Blueprint’s BLU-448, a CDK4 degrader for HR+/HER2- breast cancer 2026-05-14
- ▶ 研究关注：Sanofi synthesizes new ERK5 inhibitors 2026-05-14
- ▶ 研究关注：Andzonbio2 enters neuroinflammation collaboration 2026-05-14
- ▶ 研究关注：QW-5-70 exhibits antitumor activity in multidrug-resistant tumors 2026-05-14
- ▶ 研究关注：PRMT5 inhibitors detailed in Gilead Sciences patent 2026-05-14
- ▶ 研究关注：Sironax patents new SARM1 inhibitors 2026-05-14
- ▶ 研究关注：Henlius’ HLX-48 for solid tumors cleared for clinic in Australia 2026-05-14
- ▶ 研究关注：Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal 2026-05-14
- ▶ 研究关注：Loss of androgens tied to faster glioblastoma growth 2026-05-14
- ▶ 研究关注：Live SMT enables discovery of RUVBL inhibitors 2026-05-14
- ▶ 研究关注：Visualizing Receptor Transport Within Neurons via Transcytosis 2026-05-13
- ▶ 研究关注：BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration 2026-05-13
- ▶ 研究关注：ASGCT President Terry Flotte Touts Rare Disease Initiatives as His Term Ends 2026-05-13
- ▶ 研究关注：Synthesizing a Natural Sunscreen and Antioxidant in E. coli 2026-05-13
- ▶ 研究关注：ApexGO: AI-Driven Approach to Faster Antibiotic Discovery 2026-05-13
- ▶ 研究关注：Why AI Alone Isn’t Enough for Oligonucleotide Discovery 2026-05-13
- ▶ 研究关注：Cellares and ProTgen Automate Manufacturing of Progenitor T-Cell Therapy for Blood Cancer 2026-05-13
- ▶ 研究关注：FDA’s leadership void leaves biotech with renewed ‘uncertainty’ 2026-05-13
- ▶ 研究关注：Adopting Creative Chemistry to Optimize Bioprocessing Workflow 2026-05-13
- ▶ 研究关注：Yeast We Can Cut Costs By Optimizing Cell-Free Expression Systems 2026-05-13
- ▶ 研究关注：Operator Protection as Core Design Principle for ADC Bioprocessing 2026-05-13
- ▶ 研究关注：Technique Yields Uniform, High-Quality, EVs at Scale 2026-05-13
- ▶ 研究关注：Life sciences ‘sweet’ opportunity in US-China talks 2026-05-13
- ▶ 研究关注：In the mix post-Ventyx, more NLRP3s to seize? 2026-05-13
- ▶ 研究关注：Beone’s BCL2 drug Beqalzi wins FDA nod in mantle cell lymphoma 2026-05-13
- ▶ 研究关注：Nvision secures $55 million, with backing from Abbott 2026-05-13
- ▶ 研究关注：Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss 2026-05-13
- ▶ 研究关注：Nvision secures $55 million, with backing from Abbott 2026-05-13
- ▶ 研究关注：Regulatory actions for May 13, 2026 2026-05-13
- ▶ 研究关注：Financings for May 13, 2026 2026-05-13
- ▶ 研究关注：Other news to note for May 13, 2026 2026-05-13
- ▶ 研究关注：Appointments and advancements for May 13, 2026 2026-05-13
- ▶ 研究关注：Daewoong nabs Innovo’s preclinical IBD asset in ₩663B deal 2026-05-13
- ▶ 研究关注：In the clinic for May 13, 2026 2026-05-13
- ▶ 研究关注：“It Was Not a Cure”: Musunuru Cautions ASGCT on Baby KJ Promise 2026-05-13
- ▶ 研究关注：Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B 2026-05-13
- ▶ 研究关注：ASGCT 2026: Victoria Gray Roadshow Returns to Boston 2026-05-13
- ▶ 研究关注：ASGCT 2026: Circular RNA, the new beast in gene and cell therapy 2026-05-13
- ▶ 研究关注：AOP Health and VRG Therapeutics partner on immunology program 2026-05-13
- ▶ 研究关注：Dewpoint Therapeutics discovers new β-catenin modulators 2026-05-13
- ▶ 研究关注：Pheast presents data on CDH1/Nectin-4-targeted ADC PHST-677 2026-05-13
- ▶ 研究关注：Boehringer Ingelheim licenses Immunitas antibody program 2026-05-13
- ▶ 研究关注：Aeovian Pharmaceuticals synthesizes new CD38 inhibitors 2026-05-13
- ▶ 研究关注：Shanghai Allink Biotherapeutics patents anti-EGFR/MET bispecific ADCs 2026-05-13
- ▶ 研究关注：Foghorn Therapeutics discloses new EP300 degradation inducers 2026-05-13
- ▶ 研究关注：Novel PROTAC degrader targeting SAMHD1 disclosed 2026-05-13
- ▶ 研究关注：BTX-001 enables single-dose treatment for geographic atrophy 2026-05-13
- ▶ 研究关注：Phrontline Biopharma details new B7-H3/EGFR bispecific ADCs 2026-05-13
- ▶ 研究关注：Loss of androgens tied to faster glioblastoma growth 2026-05-13
- ▶ 研究关注：Simcere’s SCR-A019 shows promise for mesothelin-expressing tumors 2026-05-13
- ▶ 研究关注：Tracking hantavirus across the globe 2026-05-13
- ▶ 研究关注：[Podcast] Closing the Distance in Cancer Care 2026-05-13
- ▶ 研究关注：Gene Therapy ETX101 Improves Seizures and Neurodevelopment in Dravet Syndrome in Phase I/II 2026-05-13
- ▶ 研究关注：10x Genomics, Harvard Target Element’s Multiomics Platform in Patent Lawsuit 2026-05-13
- ▶ 研究关注：AAVs in Focus: Practical Approaches to Capsid Analytics and Plasmid DNA Control 2026-05-12
- ▶ 研究关注：Brain Histamine Map Links Genetic Factors to Mental Health and Psychiatric Disorders 2026-05-12
- ▶ 研究关注：Acute Myeloid Leukemia Therapy Improved by CRISPR Stem Cell Transplant 2026-05-12
- ▶ 研究关注：FDA chief Marty Makary resigns from agency, ending tumultuous tenure 2026-05-12
- ▶ 研究关注：Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug 2026-05-12
- ▶ 研究关注：Makary out at the FDA 2026-05-12
- ▶ 研究关注：Commerce gives Rx companies 30 days to submit US onshoring plans 2026-05-12
- ▶ 研究关注：Coming through on Veppanu with back-loaded Rigel deal 2026-05-12
- ▶ 研究关注：GSK licenses siRNA asset in $1B deal for Siranbio 2026-05-12
- ▶ 研究关注：Multiple appearances on Priority Watch List leading to action? 2026-05-12
- ▶ 研究关注：Appointments and advancements for May 12, 2026 2026-05-12
- ▶ 研究关注：China med-tech raises: Star Sports’ $105M IPO; Cofoe nabs $133M 2026-05-12
- ▶ 研究关注：In the clinic for May 12, 2026 2026-05-12
- ▶ 研究关注：Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal 2026-05-12
- ▶ 研究关注：MHRA sets out proposal to redefine gene therapies 2026-05-12
- ▶ 研究关注：Kailera's record IPO headlines strong April for biopharma financings 2026-05-12
- ▶ 研究关注：Follow-ons hit 7-year high, lead med-tech's $10B start to 2026 2026-05-12
- ▶ 研究关注：Regulatory actions for May 12, 2026 2026-05-12
- ▶ 研究关注：Roche secures CE mark for Alzheimer’s blood test 2026-05-12
- ▶ 研究关注：Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific 2026-05-12
- ▶ 研究关注：APAC monitors hantavirus as Singapore isolates 2 from cruise ship 2026-05-12
- ▶ 研究关注：Metis Techbio, Impact Tx cleared for Hong Kong IPOs 2026-05-12
- ▶ 研究关注：Other news to note for May 12, 2026 2026-05-12
- ▶ 研究关注：Veppanu deal between Rigel and Arvinas, Pfizer worth up to $445M 2026-05-12
- ▶ 研究关注：TRPM4 antagonists disclosed in Universitätsklinikum Hamburg-Eppendorf patent 2026-05-12
- ▶ 研究关注：Funding at Infex Therapeutics to advance anti-infectives 2026-05-12
- ▶ 研究关注：OPGx-BEST1 restores BEST1 expression in retinal cells 2026-05-12
- ▶ 研究关注：Fractyl Health’s RJVA-001 cleared to enter clinic in Netherlands 2026-05-12
- ▶ 研究关注：Guardian Biosciences identifies new compounds for TBI 2026-05-12
- ▶ 研究关注：Tango Therapeutics patents new HBS1L degradation inducers 2026-05-12
- ▶ 研究关注：Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific 2026-05-12
- ▶ 研究关注：Fibrobiologics explores use of fibroblast platform for hantavirus 2026-05-12
- ▶ 研究关注：First cruise ship hantavirus genome points to zoonotic spillover 2026-05-12
- ▶ 研究关注：JUV-161 reverses structural and functional muscle decline 2026-05-12
- ▶ 研究关注：Zhongshan Institute for Drug Discovery synthesizes YAP1/TEAD interaction inhibitors 2026-05-12
- ▶ 研究关注：HEC Pharma presents oral small-molecule PD-L1 inhibitor 2026-05-12
- ▶ 研究关注：Architect Therapeutics reports new CDK2 inhibitors 2026-05-12
- ▶ 研究关注：Two-step HIV vaccine induces broadly neutralizing antibodies 2026-05-12
- ▶ 研究关注：Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion 2026-05-12
- ▶ 研究关注：In the clinic for May 12, 2026 2026-05-12
- ▶ 研究关注：Regulatory actions for May 12, 2026 2026-05-12
- ▶ 研究关注：Other news to note for May 12, 2026 2026-05-12
- ▶ 研究关注：A year after Vertex’s big launch, pain drug research faces a pivotal moment 2026-05-12
- ▶ 研究关注：Stable Producer Cell Line Generation Platform Adds to VIVEbiotech’s Lentiviral Vector Manufacturing Capabilities 2026-05-12
- ▶ 研究关注：Cholesterol Drug May Weaken Ovarian Cancer’s Metastatic Defense 2026-05-12
- ▶ 研究关注：How HIV-1 Develops Resistance to Broadly Neutralizing Antibodies 2026-05-11
- ▶ 研究关注：Genewiz Launches Gene Synthesis 2.0 2026-05-11
- ▶ 研究关注：MBX highlights early data for monthly obesity drug MBX-4291 2026-05-11
- ▶ 研究关注：Other news to note for May 11, 2026 2026-05-11
- ▶ 研究关注：Appointments and advancements for May 11, 2026 2026-05-11
- ▶ 研究关注：Regulatory actions for May 11, 2026 2026-05-11
- ▶ 研究关注：In the clinic for May 11, 2026 2026-05-11
- ▶ 研究关注：Financings for May 11, 2026 2026-05-11
- ▶ 研究关注：FDA pregnancy safety guidance evolves with the science 2026-05-11
- ▶ 研究关注：Bright Uro secures FDA approval for abdominal sensor 2026-05-11
- ▶ 研究关注：Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific 2026-05-11
- ▶ 研究关注：First cruise ship hantavirus genome points to zoonotic spillover 2026-05-11
- ▶ 研究关注：GSK cuts deal with Sino to broaden reach of hepatitis B drug 2026-05-11
- ▶ 研究关注：RegVelo AI Model Predicts Cell Fate, Tackles Developmental Disorders and Cancer 2026-05-11
- ▶ 研究关注：ICYMI: Week in review, May 4-8, 2026 2026-05-11
- ▶ 研究关注：First cruise ship hantavirus genome points to zoonotic spillover 2026-05-11
- ▶ 研究关注：Biggest gainers and losers for May 4-8, 2026 2026-05-11
- ▶ 研究关注：Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial 2026-05-11
- ▶ 研究关注：Biotech layoffs are easing, but is the worst over? 2026-05-11
- ▶ 研究关注：Boyuan Pharmaceutical prepares new HSV inhibitors 2026-05-11
- ▶ 研究关注：Shanghai Jeyou Pharmaceutical patents LGALS3 inhibitors 2026-05-11
- ▶ 研究关注：Mabwell’s 9MW5211 gains IND clearance for IBD 2026-05-11
- ▶ 研究关注：Traws Pharma to advance hantavirus candidates 2026-05-11
- ▶ 研究关注：Hefei Shengpu Pharmaceutical synthesizes new GTPase KRAS mutant inhibitors 2026-05-11
- ▶ 研究关注：Next-generation PLpro inhibitor for SARS-CoV-2 divulged 2026-05-11
- ▶ 研究关注：First long-acting, intra-articular multikinase inhibitor for OA 2026-05-11
- ▶ 研究关注：ASO therapy prevents hydrocephalus in a monogenic syndrome model 2026-05-11
- ▶ 研究关注：Yantai Rongchang Pharmaceutical reports new KRAS mutant inhibitors 2026-05-11
- ▶ 研究关注：Antimicrobial compounds revealed in University of Hong Kong patent 2026-05-11
- ▶ 研究关注：Soley Therapeutics reports data on new CKAP2 modulator STX-6398 2026-05-11
- ▶ 研究关注：Alzheimer’s, beyond the brain 2026-05-11
- ▶ 研究关注：In vivo mRNA gene therapy platform reprograms cytotoxic T cells 2026-05-11
- ▶ 研究关注：Singlomics’ DXP-106 shows robust results in preclinical setting 2026-05-11
- ▶ 研究关注：The capacity crunch in biopharma is a location problem 2026-05-11
- ▶ 研究关注：Precision in motion: Decoding the critical operations behind the logistics of next-generation cell and gene therapies 2026-05-11
- ▶ 研究关注：StockWatch: enGene Shares Crater on Declines in Complete Response Rates to Bladder Cancer Therapy 2026-05-11
- ▶ 研究关注：Diabetes Drug Metformin’s Blood Glucose-Lowering Effects Tied to Action on Gut Cells 2026-05-10
- ▶ 研究关注：How Digital Orchestration Is Redefining Regulatory Infrastructure for Cell and Gene Therapy 2026-05-08
- ▶ 研究关注：BioWorld and Nasdaq stock indices 2026-05-08
- ▶ 研究关注：Biopharma money raised: Jan. 1-May 7, 2026 2026-05-08
- ▶ 研究关注：Money raised by biopharma 2026-05-08
- ▶ 研究关注：Biopharma money raised by month in 2026 (US$M) 2026-05-08
- ▶ 研究关注：Remembering J. Craig Venter, PhD 2026-05-08
- ▶ 研究关注：Follow-ons hit 7-year high, lead med-tech's $10B start to 2026 2026-05-08
- ▶ 研究关注：Odyssey’s IPO, placement brings $304M to lead drugs in IBD, lupus 2026-05-08
- ▶ 研究关注：Budo judo moves aplenty for Climb in autoimmune 2026-05-08
- ▶ 研究关注：Mobia debuts on Nasdaq to bring stroke therapy to more patients 2026-05-08
- ▶ 研究关注：APAC monitors hantavirus as Singapore isolates 2 from cruise ship 2026-05-08
- ▶ 研究关注：Scarlet raises $4M to take manufactured red blood cells into clinic 2026-05-08
- ▶ 研究关注：In vivo mRNA gene therapy platform reprograms cytotoxic T cells 2026-05-08
- ▶ 研究关注：Regulatory actions for May 8, 2026 2026-05-08
- ▶ 研究关注：Other news to note for May 8, 2026 2026-05-08
- ▶ 研究关注：Appointments and advancements for May 8, 2026 2026-05-08
- ▶ 研究关注：In the clinic for May 8, 2026 2026-05-08
- ▶ 研究关注：Financings for May 8, 2026 2026-05-08
- ▶ 研究关注：Lilly to invest extra $4.5B across Indiana manufacturing 2026-05-08
- ▶ 研究关注：ASGCT CEO David Barrett Previews the Upcoming Conference in Boston 2026-05-08
- ▶ 研究关注：Budoprutug in Climb spotlight for autoimmune indications 2026-05-08
- ▶ 研究关注：ParcelBio Unveils Programmable mRNA Platform Backed by $13M Financing 2026-05-08
- ▶ 研究关注：FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended 2026-05-08
- ▶ 研究关注：Gene Therapy Briefs: Regeneron Wins FDA Approval for First Neurosensory Gene Therapy 2026-05-08
- ▶ 研究关注：Lilly, Gilead lead pharma’s M&A boom 2026-05-08
- ▶ 研究关注：ASGCT Honors Mohamed Abou‑el‑Enein as Outstanding New Investigator 2026-05-08
- ▶ 研究关注：FDA clears IND for Harbour Biomed’s HBM-7004 2026-05-08
- ▶ 研究关注：Hangzhou Bio Sincerity Pharma-Tech identifies new exportin-1 receptor antagonists 2026-05-08
- ▶ 研究关注：Treeline Biosciences patents new RAS inhibitors 2026-05-08
- ▶ 研究关注：Impact Therapeutics discovers new Wee1 inhibitors 2026-05-08
- ▶ 研究关注：Hantavirus is ‘sentinel’ more than acute pandemic threat 2026-05-08
- ▶ 研究关注：BD-200 is strong dual-targeting ADC candidate for cancer 2026-05-08
- ▶ 研究关注：New assay for drug discovery against chemo-induced peripheral neuropathy 2026-05-08
- ▶ 研究关注：University of California discloses new PRKACA-targeting PROTACs 2026-05-08
- ▶ 研究关注：Seed financing at Parcelbio to advance mRNA medicines 2026-05-08
- ▶ 研究关注：Shanghai Ailux Biotechnology synthesizes FGFR2-targeting ADCs 2026-05-08
- ▶ 研究关注：Takeda’s anti-CCR8 ADC shows potent antitumor activity 2026-05-08
- ▶ 研究关注：Hepatitis A vaccine nonclinical efficacy can be tested in IFN receptor KO mice 2026-05-08
- ▶ 研究关注：Arrivent’s MUC16/NaPi2b-targeted ADC gains IND clearance 2026-05-08
- ▶ 研究关注：Two-step HIV vaccine induces broadly neutralizing antibodies 2026-05-08
- ▶ 研究关注：Odyssey, on second try, snags $279M in an IPO 2026-05-08
- ▶ 研究关注：Macrophages Use Cell Volume Changes to Sense Danger and Amplify Inflammation 2026-05-07
- ▶ 研究关注：From Sequence to Patient in Under 12 Months: A Case Study in Advancing Complex Cancer Immunotherapies 2026-05-07
- ▶ 研究关注：G-Link CAR-T Delivery Platform Showcased at ASGCT 2026-05-07
- ▶ 研究关注：Sarepta tumbles as its gene therapy sales decline further 2026-05-07
- ▶ 研究关注：Human Antibodies Identified That Have Potential To Prevent and Treat Measles Virus 2026-05-07
- ▶ 研究关注：Oral Small-Molecule GLP-1s Linked to Deep Brain Activity and Reduced Cravings in Mice 2026-05-07
- ▶ 研究关注：Digital PCR Playbook: Applications and Challenges Across Research and Clinical Labs 2026-05-07
- ▶ 研究关注：Cellular Origins Collaborates with Immatics on Automation for Cell Therapy Manufacturing 2026-05-07
- ▶ 研究关注：FDA slowdown on Tzield sBLA underlines CNPV questions 2026-05-07
- ▶ 研究关注：Entrada sinks on mixed DMD data with ENTR-601-44 2026-05-07
- ▶ 研究关注：Hantavirus is ‘sentinel’ more than acute pandemic threat 2026-05-07
- ▶ 研究关注：Phase II Engene trouble: NMIBC detalimogene data throttle stock 2026-05-07
- ▶ 研究关注：Moderna, Vir among early 2026 top infectious disease gainers 2026-05-07
- ▶ 研究关注：Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst 2026-05-07
- ▶ 研究关注：Roche to acquire Pathai for up to $1.05B 2026-05-07
- ▶ 研究关注：Atara rises on new FDA pathway for Ebvallo resubmission 2026-05-07
- ▶ 研究关注：Regulatory actions for May 7, 2026 2026-05-07
- ▶ 研究关注：US FDA tries out 1-day inspections 2026-05-07
- ▶ 研究关注：Appointments and advancements for May 7, 2026 2026-05-07
- ▶ 研究关注：In the clinic for May 7, 2026 2026-05-07
- ▶ 研究关注：Financings for May 7, 2026 2026-05-07
- ▶ 研究关注：Other news to note for May 7, 2026 2026-05-07
- ▶ 研究关注：Angelini to buy Catalyst in $4B play for rare neuro drugs 2026-05-07
- ▶ 研究关注：Entrada shares dive as Duchenne results disappoint 2026-05-07
- ▶ 研究关注：Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst 2026-05-07
- ▶ 研究关注：First measles treatment advances as vaccination rates drop 2026-05-07
- ▶ 研究关注：Roche to acquire digital pathology firm PathAI in deal potentially worth over $1B 2026-05-07
- ▶ 研究关注：Next Gen Leadership Awards Presented at the AGBT Agricultural Meeting 2026-05-07
- ▶ 研究关注：Infensa Bioscience identifies new ASIC blockers 2026-05-07
- ▶ 研究关注：PLX-61639 shows efficacy in SMARCA4-mutant tumors 2026-05-07
- ▶ 研究关注：UCB and Cancer Research UK enter new oncology alliance 2026-05-07
- ▶ 研究关注：KRAS inhibitors disclosed in Sunrise Oncology patent 2026-05-07
- ▶ 研究关注：HK Inno.N patents new MAP4K1 inhibitors 2026-05-07
- ▶ 研究关注：Biosion’s BSI-737 exerts strong antitumor activity 2026-05-07
- ▶ 研究关注：Ascletis Pharma divulges new GIPR and GLP-1R agonists 2026-05-07
- ▶ 研究关注：Circulating sncRNA transcriptome in diabetic kidney disease and SGLT2 inhibitor treatment 2026-05-07
- ▶ 研究关注：Insmed reports new cathepsin C inhibitors 2026-05-07
- ▶ 研究关注：ZMS-2195 is a potent multi-RAS strategy for RAS-dependent tumors 2026-05-07
- ▶ 研究关注：Engineered programmable inhibitory binders to target CRAC channelopathies 2026-05-07
- ▶ 研究关注：Innocare Pharma’s ICP-B208 gains IND clearance in China 2026-05-07
- ▶ 研究关注：Bayer to Acquire Perfuse for up to $2.45B, Seeing Ophthalmology Opportunity 2026-05-07
- ▶ 研究关注：From Discovery to GMP: Building Scalable Cell Therapy Manufacturing 2026-05-06
- ▶ 研究关注：Microproteins and Peptideins Expand Boundaries of the Human Proteome 2026-05-06
- ▶ 研究关注：Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline 2026-05-06
- ▶ 研究关注：Heavy-Chain BsAbs More Manufacturable than Light-Chains 2026-05-06
- ▶ 研究关注：Researchers’ Spinout Focuses on Simplifying Viral Vector Purification 2026-05-06
- ▶ 研究关注：Moss Powering the Next Drug Frontier 2026-05-06
- ▶ 研究关注：Regulators Should Rely on Peers’ GMP Audits to Cut Inspection Burden 2026-05-06
- ▶ 研究关注：Multiple appearances on Priority Watch List leading to action? 2026-05-06
- ▶ 研究关注：Bayer buying Perfuse for $300M up front in potential $2.45B deal 2026-05-06
- ▶ 研究关注：Abdakibart phase II graded, puts Avalo in HS upper class 2026-05-06
- ▶ 研究关注：China med-tech raises: Star Sports’ $105M IPO; Cofoe nabs $133M 2026-05-06
- ▶ 研究关注：Kailera's record IPO headlines strong April for biopharma financings 2026-05-06
- ▶ 瑞思迈3.4亿美元收购Noctrix 2026-05-06
- ▶ 瑞士生物技术创投创新高 2026-05-06
- ▶ GSK 10亿美元押注siRNA药物 2026-05-06
- ▶ 生物医药简讯：5月6日 2026-05-06
- ▶ 5月6日行业人事动态 2026-05-06
- ▶ 5月6日生物医药监管动态 2026-05-06
- ▶ 5月6日临床快报 2026-05-06
- ▶ 2026年5月6日生物医药融资动态 2026-05-06
- ▶ 诺和诺德上调预期，Wegovy药片开局强劲 2026-05-06
- ▶ CoCoGraph AI模型生成合规分子 2026-05-06
- ▶ 光控平台使生物制造性能翻倍 2026-05-06
- ▶ Avalo IL-1β靶向药II期临床成功 2026-05-06
- ▶ Avalo皮肤药成功，股价飙升 2026-05-06
- ▶ 研究关注：Apertura Gene Therapy and TSC Alliance partner on gene therapies 2026-05-06
- ▶ 研究关注：Korea Research Institute of Chemical Technology reports new JAK1 inhibitors 2026-05-06
- ▶ 研究关注：Kymera’s IRF5 degrader shows potential in IBD treatment 2026-05-06
- ▶ 研究关注：Alzecure’s TrkA modulator combines pain relief with joint protection 2026-05-06
- ▶ 研究关注：Nankai University and Tianjin Accendatech identify new compounds for liver cancer 2026-05-06
- ▶ 研究关注：Simcere Zaiming’s SIM-0613 cleared to enter clinic in China 2026-05-06
- ▶ 研究关注：Eyes are first prize for newco Link Biologics 2026-05-06
- ▶ 研究关注：Apelin receptor agonists disclosed in Zhuhai United Laboratories patent 2026-05-06
- ▶ 研究关注：Funding at Signadori Bio to advance monocyte immunotherapies 2026-05-06
- ▶ 研究关注：Solve Therapeutics patents new 5T4-targeting ADCs 2026-05-06
- ▶ 研究关注：New SMARCA2 degrader for SMARCA4-deficient cancers described 2026-05-06
- ▶ 荣昌制药获新型抗癌化合物专利 2026-05-06
- ▶ 研究关注：Eyes are the prize for newco Link Biologics 2026-05-06
- ▶ 研究关注：Elaaj Bio advances gene therapy for CDKL5 deficiency disorder 2026-05-06
- ▶ 研究关注：MYO technology enables DNA delivery of incretin agonists for durable weight loss 2026-05-06
- ▶ 研究关注：Novelty Nobility Expands AGC Biologics Deal to Take Product Candidate Through GMP Manufacturing 2026-05-06
- ▶ 研究关注：CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine 2026-05-06
- ▶ 研究关注：UCB to Acquire Candid for up to $2.2B, Expanding Presence in TCE Antibodies for Immunology 2026-05-06
- ▶ 研究关注：Chromosome Engineering Reveals New Locus for Fusarium Resistance in Wheat 2026-05-05
- ▶ 研究关注：Psilocybin-Induced Brain Changes May Explain Therapeutic Effects 2026-05-05
- ▶ 研究关注：Viridian data lift prospects for thyroid eye disease drug 2026-05-05
- ▶ 研究关注：White House looks to expand MFN pricing for $530B-plus in savings 2026-05-05
- ▶ 研究关注：Cytokinetics metrics satisfy in nHCM phase III 2026-05-05
- ▶ 研究关注：MMI’s Symani system treats Alzheimer’s patient in IDE study 2026-05-05
- ▶ 研究关注：Viridian’s Reveal-2 beats expectations with elegrobart in TED 2026-05-05
- ▶ 研究关注：Other news to note for May 5, 2026 2026-05-05
- ▶ 研究关注：Appointments and advancements for May 5, 2026 2026-05-05
- ▶ 研究关注：Financings for May 5, 2026 2026-05-05
- ▶ 研究关注：In the clinic for May 5, 2026 2026-05-05
- ▶ 研究关注：Regulatory actions for May 5, 2026 2026-05-05
- ▶ 研究关注：Madrigal expands MASH pipeline in potential $1B Arrowhead deal 2026-05-05
- ▶ 研究关注：USTR calls out trade partners for Rx, med-tech pricing policies 2026-05-05
- ▶ 研究关注：Bio Korea 2026: US policy risks shift to execution framework 2026-05-05
- ▶ 研究关注：UCB onboards more autoimmune TCEs with $2.2B Candid buy 2026-05-05
- ▶ 研究关注：Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal 2026-05-05
- ▶ 研究关注：Bio Korea 2026 kicks off with spotlight on oligonucleotides 2026-05-05
- ▶ 研究关注：Sonire starts US study of cancer HIFU after $18M series A 2026-05-05
- ▶ 研究关注：China’s new IIT rules could reshape early stage drug development 2026-05-05
- ▶ 研究关注：How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III 2026-05-05
- ▶ 研究关注：Viridian’s Reveal-2 beats expectations in TED 2026-05-05
- ▶ 研究关注：Cytospire raises £61M series A to target EGFR in solid tumors 2026-05-05
- ▶ 研究关注：University of California identifies new EGFR inhibitors for glioblastoma 2026-05-05
- ▶ 研究关注：Agomab Therapeutics patents new TGFBR1 inhibitors 2026-05-05
- ▶ 研究关注：Yuanyi Wise Tech reports SOS1/KRAS G12V interaction inhibitors for cancer 2026-05-05
- ▶ 研究关注：Genosco discloses GSPT protein degraders 2026-05-05
- ▶ 研究关注：FX-111 targets persistent androgen signaling in prostate cancer 2026-05-05
- ▶ 研究关注：RCT-1213 has strong activity in TM4SF5-expressing tumors 2026-05-05
- ▶ 研究关注：NIH grant supports Quiver Bioscience’s QV-2421 for pain 2026-05-05
- ▶ 研究关注：Deepcure develops new BRD4 BD2 inhibitors 2026-05-05
- ▶ 研究关注：Selective DNMT1 degrader shows potent anti-leukemic activity 2026-05-05
- ▶ 研究关注：TMLZ-G46 shows strong antitumor effects in glioma 2026-05-05
- ▶ 研究关注：KLRG1 is immune checkpoint in several solid tumor models 2026-05-05
- ▶ 研究关注：Evotec and Almirall derm alliance yields development candidate 2026-05-05
- ▶ 研究关注：Vertex earnings get muted investor response 2026-05-05
- ▶ 研究关注：Cytokinetics heart drug scores in closely watched trial 2026-05-05
- ▶ 研究关注：New Human-Computer Interaction Software Designed to Support Diverse Online Teamwork Styles 2026-05-05
- ▶ 研究关注：MFDS clears Curocell’s anbal-cel as first homegrown CAR T therapy 2026-05-05
- ▶ 研究关注：Regulatory actions for May 5, 2026 2026-05-05
- ▶ 研究关注：Other news to note for May 5, 2026 2026-05-05
- ▶ 研究关注：In the clinic for May 5, 2026 2026-05-05
- ▶ 研究关注：Financings for May 5, 2026 2026-05-05
- ▶ 研究关注：Appointments and advancements for May 5, 2026 2026-05-05
- ▶ 研究关注：Cytospire hauls in $83M for a new type of T cell engager 2026-05-05
- ▶ 研究关注：News in brief 2026-05-05
- ▶ 研究关注：Gene Syntax Determines DNA Supercoiling and Modulates Gene Expression 2026-05-04
- ▶ 研究关注：Blood Stem Cells Evade Immune Attack in Aplastic Anemia Through Gene Mutations 2026-05-04
- ▶ 研究关注：Protein Biomarkers in Practice: Strategies to Reduce Drug Development Risk 2026-05-04
- ▶ 研究关注：TRACS Enables Strain-Level Tracking of Microbial Transmission 2026-05-04
- ▶ 研究关注：Optical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells 2026-05-04
- ▶ 研究关注：Celcuity strengthens case for ASCO-spotlighted breast cancer drug 2026-05-04
- ▶ 研究关注：USTR calls out trade partners for Rx, med-tech pricing policies 2026-05-04
- ▶ 研究关注：Up to BAT in PSC, Mirum base case proven with phase IIb 2026-05-04
- ▶ 研究关注：Celcuity rises on gedatolisib on top-line data in breast cancer 2026-05-04
- ▶ 研究关注：Regulatory actions for May 4, 2026 2026-05-04
- ▶ 研究关注：Appointments and advancements for May 4, 2026 2026-05-04
- ▶ 研究关注：Other news to note for May 4, 2026 2026-05-04
- ▶ 研究关注：In the clinic for May 4, 2026 2026-05-04
- ▶ 研究关注：Financings for May 4, 2026 2026-05-04
- ▶ 研究关注：Bio Korea 2026: US policy risks shift to execution framework 2026-05-04
- ▶ 研究关注：UCB onboards more autoimmune TCEs with $2.2B Candid buy 2026-05-04
- ▶ 研究关注：ICYMI: Week in review, April 27-May 1, 2026 2026-05-04
- ▶ 研究关注：UCB onboards more autoimmune TCEs with $2.2B Candid buy 2026-05-04
- ▶ 研究关注：Biggest gainers and losers for April 27-May 1, 2026 2026-05-04
- ▶ 研究关注：With $97M, Latus pursues a different kind of Huntington’s gene therapy 2026-05-04
- ▶ 研究关注：Big Tech Targets Drug Discovery with Wave of Life Science Platforms 2026-05-04
- ▶ 研究关注：Today's news in brief 2026-05-04
- ▶ 研究关注：Vanderbilt patent describes 5-HT2B receptor antagonists 2026-05-04
- ▶ 研究关注：Holiday notice 2026-05-04
- ▶ 研究关注：Coreterra Therapeutics patents agents for schizophrenia 2026-05-04
- ▶ 研究关注：Beijing Danatlas Pharmaceutical Technology prepares new PARG inhibitors 2026-05-04
- ▶ 研究关注：METTL3 inhibitor EP-102 shows broad antitumor activity 2026-05-04
- ▶ 研究关注：BLR Bio’s BLR-200 shows promise in systemic sclerosis models 2026-05-04
- ▶ 研究关注：Beone eyes Huahui Health’s trispecific HH-160 with $2B option deal 2026-05-04
- ▶ 研究关注：AAV9-delivered AntagoNATs have preclinical efficacy as one-time treatment for Dravet syndrome 2026-05-04
- ▶ 研究关注：Latus Bio series A financing supports early-stage programs 2026-05-04
- ▶ 研究关注：Liposomes displaying Env trimers drive HIV apex-focused responses 2026-05-04
- ▶ 研究关注：Sanyou Biopharmaceuticals discloses TROP2-targeting ADCs 2026-05-04
- ▶ 研究关注：Dual MTHFD1/2 inhibitor induces tumor regression in vivo 2026-05-04
- ▶ 研究关注：Shanghai Pharmaceuticals reports new FR-α-targeting ADCs 2026-05-04
- ▶ 研究关注：E-688 potent toward B7-H3-expressing tumors 2026-05-04
- ▶ 患者死亡及专利挑战重挫Erasca股价 2026-05-03
- ▶ 含DNA胞外囊泡增强抗肿瘤免疫 2026-05-01
- ▶ 恢复蛋白回收逆转T细胞耗竭 2026-05-01
- ▶ 突破数字瓶颈：Cytiva推出Figurate SCADA系统 2026-05-01
- ▶ 2026年前四月生物制药融资盘点 2026-05-01
- ▶ 生物医药融资回顾：2019-2026年趋势 2026-05-01
- ▶ 2026年5月1日生物医药融资动态 2026-05-01
- ▶ 2026年5月1日生物医药简讯汇总 2026-05-01
- ▶ 2026年5月生物医药人事动态 2026-05-01
- ▶ 2026年5月1日临床动态 2026-05-01
- ▶ 2026年5月1日监管动态一览 2026-05-01
- ▶ Seaport纳斯达克上市，母公司在英退市 2026-05-01
- ▶ Sonire启动癌症HIFU美研，获1800万美元A轮 2026-05-01
- ▶ 依沃西单抗NSCLC III期数据引发热议 2026-05-01
- ▶ Hypervision获1700万英镑，推动手术高光谱成像技术 2026-05-01
- ▶ Hemab融资3.01亿美元，生物制药IPO回暖 2026-05-01
- ▶ 首款PROTAC药物获FDA批准，改写乳腺癌治疗 2026-05-01
- ▶ 利奥制药5000万美元进军基因疗法 2026-05-01
- ▶ Axsome新药获批治疗阿尔茨海默症激越 2026-05-01
- ▶ BioWorld免费开放新冠文章 2026-05-01
- ▶ 细胞与基因疗法的减毒策略 2026-05-01
- ▶ 十大畅销基因疗法 2026-05-01
- ▶ 非病毒基因递送开启翻译时代 2026-05-01
- ▶ 突破血脑屏障：新技术带来希望 2026-05-01
- ▶ 基因编辑规模化，推动普适疗法临床应用 2026-05-01
- ▶ 更智能的AAV引领基因治疗新时代 2026-05-01
- ▶ 2026年4月30日：行业人事变动与晋升 2026-04-30
- ▶ 2026年4月30日监管动态 2026-04-30
- ▶ 2026年4月30日生物医药简讯 2026-04-30
- ▶ 2026年4月30日临床进展 2026-04-30
- ▶ 2026年4月30日融资动态 2026-04-30
- ▶ 生物制药高管与SEC和解盗用指控 2026-04-30
- ▶ 癌症股Q1受并购传闻推动 2026-04-30
- ▶ HHS就疫苗变更禁令提起上诉 2026-04-30
- ▶ 欧盟EMA试点突破性医疗器械加速审批 2026-04-30
- ▶ Beone以20亿美元选择权获HH-160全球权益 2026-04-30
- ▶ 独特试验策略搅浑ODAC评审之水 2026-04-30
- ▶ 雾化新星Avalyn吸金3亿美元IPO 2026-04-30
- ▶ Axsome新药Auvelity获批治疗阿尔茨海默症躁动 2026-04-30
- ▶ 独特试验策略搅浑camizestrant审批水 2026-04-30
1 / 31